

TDM	729.89	915.51	185.62	▲25.43%
HUM	749.73	924.29	174.56	▲23.28%
DMW	833.72	1004.01	170.29	▲20.43%
YZJ	903.49	1127.46	223.97	▲24.79%
GLY	982.07	1219.39	237.32	▲24.17%
VDA	113.74	143.41	29.67	▲26.09%
UVV	468.08	535.41	67.33	▲14.38%
HJS	545.49	659.05	113.56	▲20.82%
EDC	566.96	664.69	97.73	▲17.24%
FLR	660.27	745.28	85.01	▲12.88%
UVD	155.59	181.57	25.98	▲16.70%
QUV	440.55	540.21	99.66	▲22.62%
HZT	285.51	344.98	59.47	▲20.83%
PCW	811.44	1029.66	218.22	▲26.89%
AIK	361.77	451.39	89.62	▲24.77%
ZJJ	858.36	994.57	136.21	▲15.87%
RHJ	894.79	1046.68	151.89	▲16.97%
VGV	425.08	509.95	84.87	▲19.97%


NordiQC data – Tips and Tricks

NordiQC seminar 2026

Tanya Julio
Technical Lead Specialist
NordiQC - t.julio@rn.dk

Run 75-77 Overview


Run 75



Keynotes:

High number of well performing RTU except for:
Podoplanin (Podop) and SATB2


Run 76



Keynotes:

High number of well performing RTU.
MLH1 and PAX5 low number of optimal

Run 77



Keynotes:

A big run with exciting markers and different problems.

Purpose: To identify seminomas in CUP and differentiate between malignant melanomas and NSCLCs

Table 1b. Concentrated antibodies and assessment marks for Podop, run 75

Table 3. Proportion of sufficient and optimal results for Podop for the most commonly used RTU IHC systems

RTU systems	Recommended protocol settings*		Laboratory modified protocol settings**	
	Sufficient	Optimal	Sufficient	Optimal
Dako AS mAb clone D2-40, IR072	100% (16/16)	25% (4/16)	57% (4/7)	14% (1/7)
VMS GX, XT, Ultra, Ultra plus mAb clone D2-40, 760-4395	44% (21/48)	0% (0/48)	86% (83/97)	45% (44/97)

Assessment	Good	Borderline	Poor	Suff. ¹	OR ²
0	0	0	1	-	-
0	1	0	0	-	-
1	1	1	1	-	-
0	0	1	1	-	-
4	2	0	0	80%	40%
18	19	3	3	63%	33%
1	0	0	0	-	-
1	0	1	0	-	-
4	1	1	2	-	-

Graph 1. Proportion of sufficient results for Podop in the four NordiQC runs performed





Table 1c. Ready-to-use antibodies and assessment marks for Podop, run 75


Ready-To-Use antibodies	n	Vendor	Optimal	Good	Borderline	Poor	Suff. ¹	OR ²
mAb clone D2-40 PM266	3	BioCare Medical	0	2	1	0	-	-
mAb clone D2-40 322M	22	Cell Marque	7	8	7	0	68%	32%
mAb clone D2-40 IR072 (VRPS)³	16	Dako/Agilent	4	12	0	0	100%	25%
mAb clone D2-40 IR072 (LMPS)⁴	82	Dako/Agilent	33	34	13	2	82%	40%
mAb clone D2-40 MAD-000402QD	5	Master Diagnostica	1	1	2	1	40%	20%
mAb clone D2-40 8515-C010	3	Sakura Finetek	3	0	0	0	-	-
mAb clone D2-40 760-4395 (VRPS)³	48	Ventana/Roche	0	21	27	0	44%	0%
mAb clone D2-40 760-4395 (LMPS)⁴	100	Ventana/Roche	46	40	14	0	86%	46%

Podoplanin – Ventana RTU



Ventana RTU 760-4395, OptiView with amplification



Ventana RTU 760-4395, VRPS with UltraView




Tonsil




Mesothelioma

Podoplanin – AS + Bond challenges

Ventana RTU 760-4395, OptiView with amplification



mAb conc. D2-40, Bond III using BERS1



SATB2 performance in NordiQC assessments




Table 2. Proportion of optimal results for SATB2 for the most commonly used antibody as concentrate on the four main IHC systems*

Concentrated antibody	Dako/Agilent Autostainer ¹		Dako/Agilent Omnis		Ventana/Roche BenchMark ²		Leica Biosystems Bond ³	
	TRS pH 9.0	TRS pH 6.1	TRS pH 9.0	TRS pH 6.1	CC1 pH 8.5	CC2 pH 6.0	BERS2 pH 9.0	BERS1 pH 6.0
rmAb clone EP281	0/2**	-	12/21 (57%)	-	27/45 (60%)	-	0/11	0/1

Table 1c. Ready-To-Use antibodies and assessment marks for SATB2, run 75

Ready-To-Use antibodies	n	Vendor	Optimal	Good	Borderline	Poor	Suff. ¹	OR ²
rmAb clone EP281 760-6075 (VRPS) ³	28	Ventana/Roche	19	6	3	-	89%	68%
mAb clone EP281 760-6075 (LMPS) ⁴	53	Ventana/Roche	17	25	11	-	79%	32%
rmAb clone EP281 384R-17/18	47	Cell Marque	14	27	6	-	87%	30%
Total	160		54	71	35	-		
Proportion			34%	44%	22%	0%	78%	

Table 1a. Overall results for SATB2, run 75

	n	Optimal	Good	Borderline	Poor	Suff. ¹	OR ²
Concentrated antibodies	112	41	35	35	1	68%	37%
Ready-To-Use antibodies	160	54	71	35	-	78%	34%
Total	272	95	106	70	1		
Proportion		35%	39%	26%	0,4%	74%	

Table 1b. Concentrated antibodies and assessment marks for SATB2, run 75


Concentrated antibodies	n	Vendor	Optimal	Good	Borderline	Poor	Suff. ¹	OR ²
mAb clone SATBA4B10	2	Zytomed	-	-	5	-	-	-
	2	Santa Cruz	-	-	1	-	-	-
	1	Abcam	-	1	-	-	-	-
mAb clone CL0276	1	Novus	-	-	1	-	-	-
mAb clone OT15H7	1	ZSGB-Bio	-	1	-	-	-	-
rmAb clone EP281	70	Cell Marque	39	28	16	-	81%	47%
	5	Bio SB						
	3	BioCare Medical						
	2	Nordic Biosite						
	1	Master Diagnostica						
	1	PathNSitu						
	1	Zeta Corporations						
rmAb clone SP281	3	Abcam	1	1	1	-	-	-
rmAb clone QR023	5	Quartett	1	3	1	-	80%	20%
rmAb clone ZR167	9	Zeta Corporations	-	-	9	-	-	-
rmAb clone EPNCIR130A	2	Abcam	-	1	1	-	-	-
pAb clone HPA001042	2	Sigma-Aldrich	-	1	1	-	-	-
Clone GR19	1	GeneBioSolutions	-	-	-	1	-	-
Total	112		41	35	35	1		
Proportion			37%	31%	31%	1%	68%	




rmAb clone EP281, 1:100, HIER CC1 48 min, Ab 32, OptiView



Appendix




Testis






Colon neuroendocrine neoplasia


mAb SATBA4B10, conc



rmAb clone EP281, 1:100, HIER CC1 36 min, Ab 32, UltraView



EP281, Ventana RTU





PAX5 performance in NordiQC assessments




Table 1b. Concentrated antibodies and assessment marks for PAX5, run 76

Concentrated antibodies	n	Vendor	Optimal	Good	Borderline	Poor	Suff. ¹	OR ²
mAb clone DAK-PAX5	24	Dako/Agilent	15	5	4	-	83%	63%
mAb clone 1EW	10	Leica Biosystems	4	3	3	-	70%	40%
mAb clone 24	3	BD Biosciences	3	-	-	-	-	-
	1	Cell Marque	-	1	-	-		
rmAb clone SP34	5	Cell Marque	1	6	-	-	100%	14%
	1	Thermo Fisher						
	1	Zytomed Systems						
Total conc.	50		27	16	7	-	86%	54%
Ready-To-Use antibodies	n	Vendor	Optimal	Good	Borderline	Poor	Suff. ¹	OR ²
rmAb clone SP34 790-44203	41	Ventana/Roche	22	17	2	-	95%	54%
rmAb clone SP34 790-44204	96	Ventana/Roche	46	39	11	-	89%	48%
mAb clone DAK-PAX5 GA6503	53	Dako/Agilent	44	9	-	-	100%	83%
mAb clone DAK-PAX5 GA6504	26	Dako/Agilent	25	1	-	-	100%	96%
mAb clone DAK-PAX5 IR6503	5	Dako/Agilent	5	-	-	-	100%	100%
mAb clone DAK-PAX5 IR6504	15	Dako/Agilent	9	5	1	-	93%	60%
mAb clone 1EW PA05523	14	Leica Biosystems	4	7	3	-	79%	29%
mAb clone 1EW PA05524	12	Leica Biosystems	3	8	1	-	92%	25%
rmAb clone EP156 8500-C010	3	Sakura Finetek	3	-	-	-	-	-
Total RTU	285		170	93	21	1	92%	60%
Total	335		197	109	28	1		
Proportion			59%	32%	8%	1%	91%	

PAX5 – Run 76










Optimal staining: mAb DAK-PAX5 GA650 RTU, Dako Omnis Envision Flex+		
		
Tonsil	DLBCL	Hodgkin
		
Insufficient staining: mAb DAK-PAX5 M7303 Conc 1:300, Dako Omnis Envision Flex+		

Table 4. Assessment marks for PAX5, run 76 Ready-To-Use rmAb clone SP34 (790-4420) on Ventana BenchMark and proportion of aberrant staining reaction for only 2-step or 3-step detection systems.

Detection system	n	Optimal	Good	Borderline	Poor	Suff. ¹	OR ²	Aberrant staining ³
2-step UltraView DAB	61	31	25	5	-	92%	51%	41% (25/61)
3-step OptiView DAB UltraView+amp	71	34	30	7	-	90%	48%	59% (42/71)



Graph 1. Proportion of sufficient results for MUM1 in the four NordiQC runs performed.



Ready-To-Use antibodies	n	Vendor	Optimal	Good	Borderline	Poor	Suff.1	OR2
Run 58 2020								
rmAb clone MRQ-43 760-4529 (VRPS) ³	3	Ventana/Roche	0	0	3	0	-	-
rmAb clone MRQ-43 760-4529 (LMPS) ⁴	23	Ventana/Roche	1	0	22	0	4%	4%
rmAb clone EP190 760-6082 (VRPS) ³	8	Ventana/Roche	4	3	1	0	88%	50%
rmAb clone EP190 760-6082 (LMPS) ⁴	9	Ventana/Roche	1	4	4	0	56%	11%
Run 77 2026								
rmAb clone EP190 760-6082 (VRPS) ³	53	Ventana/Roche	-	47	6	-	89%	0%
rmAb clone EP190 760-6082 (LMPS) ⁴	47	Ventana/Roche	-	44	2	1	94%	0%

MRQ-43, Ventana RTU
Photos from Run 48






Table 1c. Ready-To-Use antibodies and assessment marks for MUM1, run 77

Ready-To-Use antibodies	n	Vendor	Optimal	Good	Borderline	Poor	Suff. ¹	OR ²
rmAb clone EP190 760-6082 (VRPS) ³	53	Ventana/Roche	-	47	6	-	89%	0%
rmAb clone EP190 760-6082 (LPMS) ⁴	47	Ventana/Roche	-	44	2	1	94%	0%
rmAb clone MRQ-43 760-4529*	1	Ventana/Roche	-	1	-	-	-	-
mAb clone MUM1p GA644 (VRPS) ³	63	Dako/Agilent	62	1	-	-	100%	98%
mAb clone MUM1p GA644 (LPMS) ⁴	20	Dako/Agilent	18	2	-	-	100%	90%
mAb clone MUM1p IR644 (VRPS) ³	9	Dako/Agilent	3	6	-	-	100%	33%
mAb clone MUM1p IR644 (LPMS) ⁴	18	Dako/Agilent	13	3	2	-	89%	72%
mAb clone EAU32 PA0129 (VRPS) ³	21	Leica Biosystems	-	20	1	-	95%	0%
mAb clone EAU32 PA0129 (LPMS) ⁴	11	Leica Biosystems	-	7	4	-	64%	0%
rmAb clone EP190 358R-17/18	14	Cell Marque	-	11	2	1	79%	0%
Total	270		96	153	19	2		
Proportion			35%	57%	7%	1%	92%	


- Sufficient with no
- optimal results is like
- eating a melted icecream




Table 2. Proportion of optimal results for MUM1 on the four main IHC systems by optimal titration settings as listed above

Concentrated antibodies	Dako/Agilent Autostainer ¹		Dako/Agilent Omnis		Ventana/Roche BenchMark ²		Leica Biosystems Bond ³	
	TRS pH 9.0	TRS pH 6.1	TRS pH 9.0	TRS pH 6.1	CC1 pH 8.5	CC2 pH 6.0	BERS2 pH 9.0	BERS1 pH 6.0
mAb clone MUM1p 1:20-600	0/3	-	83% (5/6)	-	87% (41/47)	-	29% (4/14)	0/3


Appendix






MUM1p conc. OptiView Ventana



EP190 RTU UltraView Ventana






EAU32 RTU Leica Bond





Hodgkin Lymphoma

DLBCL, non-GCB



RTU systems	Recommended protocol settings*		Laboratory modified protocol settings**	
	Sufficient	Optimal	Sufficient	Optimal
VMS BenchMark rmAb EP190 760-6082 UltraView	93% (25/27)	0% (0/27)	89% (16/18)	0% (0/18)
VMS BenchMark rmAb EP190 760-6082 OptiView	84% (21/25)	0% (0/25)	96% (27/28)	0% (0/28)



Optimal
MUM1p conc. OptiView Ventana
Benchmark

Insufficient
EP190 RTU UltraView Ventana
Benchmark

Sufficient
EP190 RTU OptiView Ventana
Benchmark

Graph 1. Proportion of sufficient results for EMA in the three NordiQC runs performed.




Table 1b. Concentrated antibodies and assessment marks for EMA, run 77


Concentrated antibodies	n	Vendor	Optimal	Good	Borderline	Poor	Suff. ¹	OR ²
mAb clone E29	70	Dako/Agilent	36	24	9	1	87%	49%
	10	Cell Marque	5	5	-	-		
	2	BioSB	-	2	-	-		
	1	Zytomed	-	-	1	-		
mAb clone GP1.4	13	Leica Biosystems	-	-	12	1	0%	0%
	1	BioGenex	-	-	1	-		

Table 1c. Ready-To-Use antibodies and assessment marks for EMA, run 77


Ready-To-Use antibodies	n	Vendor	Optimal	Good	Borderline	Poor	Suff. ¹	OR ²
mAb clone E29 790-4463 (VRPS) ³	45	Ventana/Roche	11	25	9	-	80%	24%
mAb clone E29 790-4463 (LMPS) ⁴	122	Ventana/Roche	55	51	16	-	87%	45%
mAb clone E29 GA629 (VRPS) ³	45	Dako/Agilent	43	2	-	-	100%	96%
mAb clone E29 GA629 (LMPS) ⁴	27	Dako/Agilent	19	6	2	-	93%	70%
mAb clone E29 IR629 (VRPS) ³	14	Dako/Agilent	14	-	-	-	100%	100%
mAb clone E29 IR629 (LMPS) ⁴	15	Dako/Agilent	7	4	4	-	73%	47%
mAb clone GP1.4 PA0035 (VRPS) ³	19	Leica Biosystems	-	-	19	-	0%	0%
mAb clone GP1.4 PA0035 (LMPS) ⁴	14	Leica Biosystems	-	-	14	-	0%	0%
mAb clone E29 8233-C010	2	Sakura Finetek	2	-	-	-	-	-
mAb clone E29 247M-90/97/98	9	Cell Marque	3	3	3	-	67%	33%



GA629 E29, Dako
Omnis VRPS
EnVision Flex+



Tonsil






Kidney




Colon adenocarcinoma



GA629 E29, Dako
Omnis LMPS
EnVision Flex





Lung adenocarcinoma



Optimal
GA629 E29, Dako Omnis VRPS
EnVision Flex+



Insufficient
GA629 E29, Dako Omnis LMPS
EnVision Flex





Insufficient
PA0035 GP1.4, Bond III VRPS
Bond Refine

Table 2. Proportion of optimal results for EMA on the four main IHC systems by optimal titration settings as listed above

Concentrated antibodies	Dako/Agilent Autostainer ¹		Dako/Agilent Omnis		Ventana/Roche BenchMark ²		Leica Biosystems BOND ³	
	TRS pH 9.0	TRS pH 6.1	TRS pH 9.0	TRS pH 6.1	CC1 pH 8.5	CC2 pH 6.0	BERS2 pH 9.0	BERS1 pH 6.0
mAb clone E29 1:50-800	100% (5/5)	-	63% (5/8)	1/2	18% (6/33)	-	85% (11/13)	100% (6/6)

PAX8 – Run 77



Pushing in the
right direction





Run 77

Concentrated antibodies	n	Vendor	Optimal	Good	Borderline	Poor	Suff. ¹	OR ²
mAb clone BC12*	7	Biocare	-	-	6	1	0%	0%
	1	Zytomed Systems			1			
mAb clone MRQ-50	10	Cell Marque	-	6	4	-	60%	0%
mAb clone PAX8R1	1	Abcam	-	-	1	-	-	-
mAb clone ZM28	1	Zeta Corporation	-	-	1	-	-	-
mAb clone 4H7B3	1	BD scientific	-	-	1	-	-	-
rmAb clone SP348*	102	Abcam	62	29	9	2	89%	60%
	36	Cell Marque	21	10	3	2		
	1	Sanbio	1	-	-	-		
	1	Unknown	-	1	-	-		
rmAb clone QR016*	11	Quartett	3	7	1	-	91%	27%
Total conc.	184		88	55	35	6	78%	48%
Ready-To-Use antibodies	n	Vendor	Optimal	Good	Borderline	Poor	Suff. ¹	OR ²
mAb clone MRQ-50, 760-4618 (VRPS)³	16	Ventana/Cell Marque	-	-	12	4	0%	0%
mAb clone MRQ-50, 760-4618 (LMPS)⁴	46	Ventana/Cell Marque	-	1	43	2	2%	0%
rmAb clone, EP331* 760-6077 (VRPS)³	6	Ventana/Cell Marque	-	4	2	-	67%	0%
rmAb clone, EP331* 760-6077 (LMPS)⁴	36	Ventana/Cell Marque	1	23	11	1	67%	3%
rmAb clone SP348 790-7263 (VRPS)³	22	Ventana/Roche	17	5	-	-	100%	77%
rmAb clone SP348 790-7263 (LMPS)⁴	6	Ventana/Roche	4	2	-	-	100%	67%
rmAb clone RM436* 8257-C010	2	Sakura Finetek	-	2	-	-	-	-
mAb clone MRQ-50, 363M-10/17/18	18	Cell Marque	-	3	15	-	17%	0%
mAb clone, BC12* API438	5	Biocare Medical	2	2	1	-	80%	40%
rmAb clone SP348* 363R-30/37/38	30	Cell Marque	21	5	3	1	87%	70%
rmAb clone QR016* P-P008	14	Quartett	8	5	1	-	93%	57%
Total RTU	231		60	63	100	8	53%	26%

Concentrated antibodies	n	Vendor	Optimal	Good	Borderline	Poor	Suff. ¹	OR ²
mAb clone BC12*	9	Biocare	-	3	7	3	23%	-
mAb clone MRQ-50	4	Zytomed Systems	-					
rmAb clone EP298*	16	Cell Marque	-	8	6	2	50%	-
rmAb clone EP298*	1	Epitomics ⁵	-	1	-	-	-	-
rmAb clone EP331*	10	Cell Marque	-	5	8	1	36%	-
	4	Epitomics						
rmAb clone SP348*	146	Abcam Gennova Spring Bioscience	102	31	9	4	91%	70%
rmAb clone ZR-1*	2	Zeta Corporation	1	-	2	1	-	-
	2	BioSite						
rmAb clone BP6157*	2	Biolynx	-	1	1	-	-	-
rmAb clone QR016*	7	Quartett	3	3	1	-	86%	43%
pAb, 10336-1-AP	11	Proteintech	-	1	3	7	9%	-
pAb, 363A-15	1	Cell Marque	-	-	1	-	-	-
pAb, CP379 AK	3	Biocare	-	-	1	2	-	-
pAb, RBK047	3	Zytomed Systems Diagomics	-	-	3	-	-	-
Conc total	223		106	54	43	20	72%	48%
Ready-To-Use antibodies							Suff. ¹	OR. ²
mAb clone MRQ-50, 760-4618 (VRPS)³	6	Ventana/Roche	-	-	-	6	0%	0%
mAb clone MRQ-50, 760-4618 (LMPS)⁴	49	Ventana/Roche	-	3	34	12	6%	0%
rmAb clone, EP331* 760-6077 (VRPS)³	3	Ventana/Cell Marque	-	1	2	-	-	-
rmAb clone, EP331* 760-6077 (LMPS)⁴	11	Ventana/Cell Marque	-	4	6	1	36%	0%
mAb clone, BC12* API438	6	Biocare Medical	-	2	4	-	33%	0%
rmAb clone SP348* M6481	3	Spring Bioscience	2	1	-	-	-	-
rmAb clone GR002* GT210202	1	GeneTech	1	-	-	-	-	-
rmAb clone QR016* P-P008	2	Quartett	1	1	-	-	-	-
rmAb clone EP331* 363M/AC0338	12	Cell Marque	-	3	7	2	25%	0%
rmAb clone SP348* 363R-38	4	Cell Marque	2	1	1	-	-	-
rmAb clone RM436* 8257-C010	2	Sakura Finetek	1	1	-	-	-	-
Clone MXR013* RMA-1024	2	Fuzhou Maixin	2	-	-	-	-	-
Clone H5A8 DTBL0220101	1	DaTe Bioengineering Technology	1	-	-	-	-	-
RTU total	145		10	27	77	31	26%	8%
Total	368		116	81	120	51		
Proportion	Run 68		32%	22%	32%	14%	54%	

PAX8 - Not an easy antibody

Table 2. Proportion of optimal results for PAX8 on the four main IHC systems by optimal titration settings as listed above

Concentrated antibodies	Dako/Agilent Autostainer ¹		Dako/Agilent Omnis		Ventana/Roche BenchMark ²			Leica Biosystems Bond ³	
	TRS pH 9.0	TRS pH 6.1	TRS pH 9.0	TRS pH 6.1	CC1 pH 8.5	P3+CC1 pH 8.5	CC2 pH 6.0	BERS2 pH 9.0	BERS1 pH 6.0
rmAb clone SP348* 1:10-1:2000	2/2	-	80% (41/51)	-	54% (37/68)	1/3	0/1	21% (3/14)	-
rmAb clone QR016* 1:100	-	-	-	-	2/3	-	-	1/1	-




Table 4. Overview of the assessment marks for mAb clone MRQ-50 on the four main IHC instruments in runs 62, 64, 68 and 77 (cumulated data for both RTU and concentrate).


MRQ-50 score	Dako/Agilent Autostainer	Dako/Agilent Omnis	Ventana/Roche BenchMark GX / XT / Ultra	Leica Biosystems Bond III / Max/Prime
Optimal	-	-	-	-
Good	26	-	13	46
Borderline	7	15	177	10
Poor	-	3	66	-
Total	33	18	256	56
Sufficient %	79%	0%	5%	82%

PAX8 – Kidney as control


SP348 - Omnis



MRQ-50 - Ventana




EP331 Ventana




PAX8 – Fallopian tube as control


SP348 - Omnis



MRQ-50 - Ventana




EP331 Ventana



PAX8 – clear cell renal cell carcinoma

SP348 ventana



MRQ-50 ventana



SP348 – 790-7263 RTU pro.

MRQ-50 – 760-4618 RTU pro.




EP331 - 760-6077 RTU pro.

Optimal




Insufficient

Sufficien




Kidney



Fallopian
Tube



Ovarian
Serous
AC



PAX8 – RTU in sight

Table 3. Proportion of sufficient and optimal results for PAX8 for the most commonly used RTU IHC systems

RTU systems	Recommended protocol settings*		Laboratory modified protocol settings**	
Leica Bond Recommended Staining Protocols for PA0808 PAX-8 (MRQ-50) primary antibody was developed for use on the automated BOND system (includes Leica BOND-MAX system and Leica BOND-III system) in combination with BOND Polymer Refine Detection. HRP Detection: The recommended HRP staining protocol for PAX-8 (MRQ-50) primary antibody is IHC Protocol F. Heat induced epitope retrieval is recommended using BOND™ Epitope Retrieval Solution 2 for 10 minutes.			Sufficient	Optimal
			0% (0/11)	0% (0/11)
		3%	Dako	
			Code #	Product
		50%	GA78961	Chromogranin A, Clone LK2H10
			GA09461	Cytokeratin 8/18, Clone EP17/EP30
		GA79361	Desmin, Clone DAK-Desmin	
		GA79061	Napsin A, Clone DAK-NapA	
		GA79161	PAX8, Clone DAK-PAX8	
		GA07261	Podoplanin, Clone D2-40	
		GA09361	Terminal Deoxynucleotidyl Transferase, C	
		GA78861	TTF-1, Clone DAK-TTF-1	
OptiView				
VMS BenchMark mAb SP348 790-7263 UltraView	100% (5/5)	60% (3/5)	(1/1)	(1/1)
VMS BenchMark mAb SP348 790-7263 OptiView	100% (17/17)	82% (14/17)	(4/4)	(3/4)

COMING UP NEXT...

Dako Omnis			
Code #	Product	Protocol Name	Date Released
GA78961	Chromogranin A, Clone LK2H10	Chromogranin A LK2H10	September 8, 2026
GA09461	Cytokeratin 8/18, Clone EP17/EP30	CK 8/18 EP17/EP30	
GA79361	Desmin, Clone DAK-Desmin	Desmin DAK-Desmin	
GA79061	Napsin A, Clone DAK-NapA	Napsin A DAK-NapA	
GA79161	PAX8, Clone DAK-PAX8	PAX8 DAK-PAX8	
GA07261	Podoplanin, Clone D2-40	Podoplanin D2-40	
GA09361	Terminal Deoxynucleotidyl Transferase, Clone EP266	TdT EP266	
GA78861	TTF-1, Clone DAK-TTF-1	TTF-1 DAK-TTF-1	





Thank you for your attention

By Tanya Julio
Technical Lead Specialist at NordiQC
t.julio@rn.dk